76754-74-0Relevant academic research and scientific papers
Catalytic Addition of Alcohols to Carbodiimides Mediated by Benzimidazolin-2-iminato Actinide Complexes
Liu, Heng,Fridman, Natalia,Tamm, Matthias,Eisen, Moris S.
, p. 4600 - 4610 (2017/12/18)
The synthesis of methyl and methoxy substituted benzimidazolin-2-iminato actinide (IV) complexes (1-4), [(Bim2-MeOPh/MeN)AnN″3] and [(Bim5-MeDipp/MeN)AnN″3] (An = U, Th; N″ = N(SiMe3)2
Synthesis and Anti-Staphylococcal Activity of 2,4-Disubstituted Diphenylamines
Mehton, Ramandeep K.,Meshram, Vineet,Saxena, Sanjai,Chhibber, Manmohan
, p. 1236 - 1244 (2016/08/16)
Infections caused by Staphylococcus aureus are ubiquitous and life threatening. Evolution of resistant strains has necessitated the need to continuously discover new drugs to combat such organisms. Diphenyl ethers, such as triclosan, have recently shown potential as antibacterial agents. In this study, a series of diphenyl amines were synthesized and evaluated for in vitro antibacterial activity against Gram-positive (Staphylococcus aureus, Bacillus subtilis, Staphylococcus epidermidis) and Gram-negative (Escherichia coli, Pseudomonas aeruginosa, Pseudomonas putida) bacteria. Preliminary results showed that six of the twelve synthesized molecules were active against Staphylococcus aureus. Most notable amongst them were compounds 2(2,4-dinitrophenylamino) phenol and 2(2-dinitrophenylamino)phenol having minimum inhibitory concentration (MIC) in the range of 7.8-15.6 μg mL-1 and 7.8-62.5 μg mL-1 respectively for all the eight selected organisms. Five active compounds from the preliminary results were further screened against resistant S. aureus cultures where compounds 2(2,4-dinitrophenylamino)phenol, 2(2-dinitrophenylamino)phenol and 2-chloro-N-(2-(2,4-dichlorophenylamino)phenyl)acetamide gave encouraging results having MIC in the range 3.9-7.8 μg mL-1 for most of the organisms. Results obtained above for the selected organisms and the resistant S. aureus strains conclude that hydroxyl group at 2-position of ring B potentiates the antibacterial activity and overcomes the antibiotic resistance.
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
-
, (2015/07/15)
A novel Pt tetradentate complexes having Pt—O bond is disclosed. These complexes are useful as emitters in phosphorescent OLEDs.
Organic Electroluminescent materials and devices
-
, (2015/07/15)
A novel Pt tetradentate complexs having Pt-O bond is disclosed. These complexes are useful as emitters in phosphorescent OLEDs.
4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors
Bandarage, Upul,Hare, Brian,Parsons, Jonathan,Pham, Ly,Marhefka, Craig,Bemis, Guy,Tang, Qing,Moody, Cameron Stuver,Rodems, Steve,Shah, Sundeep,Adams, Chris,Bravo, Jose,Charonnet, Emmanuelle,Savic, Vladimir,Come, Jon H.,Green, Jeremy
scheme or table, p. 5191 - 5194 (2010/03/24)
We report herein the design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivatives as inhibitors of p70S6 kinase. Screening hits containing the 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine scaffold were optimized for p70S6K potency and selectivity against related kinases. Structure-based design employing an active site homology model derived from PKA led to the preparation of benzimidazole 5-substituted compounds 26 and 27 as highly potent inhibitors (Ki 100-fold selectivity against PKA, ROCK and GSK3.
ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE
-
Page/Page column 93, (2008/12/06)
The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.
Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor
Palmer, Brian D.
, p. 5457 - 5465 (2007/10/03)
1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR). Structure- activity relationships (SARs) are narrow, with closely related heterocycles being inactive. A systematic study of
